Nicholas P. Lesner

Nicholas P. Lesner

Auto-generated profile, based on publicly available information

Nicholas P. Lesner

Children's Medical Center Research Institute, University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
LPLuigi Perelli
Luigi Perelli
NLNicholas P. Lesner
Nicholas P. Lesner
LCLing Cai
Ling Cai
BBBrooks Bailey
Brooks Bailey
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Most kidney cancers are metabolically dysfunctional1–4, but how this dysfunction affects cancer progression in humans is unknown. We infused 13C-labelled nutrients in over 80 patients with kidney cancer during surgical tumour resection. Labelling from [U-13C]glucose varies across subtypes, indicating that the kidney environment alone cannot account for all tumour metabolic reprogramming. Compared with the adjacent kidney, clear cell renal cell carcinomas (ccRCCs) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in ex vivo organotypic cultures, indicating that suppressed labelling is tissue intrinsic. [1,2-13C]acetate and [U-13C]glutamine infusions in patients, coupled with measurements of respiration in isolated human kidney and tumour mitochondria, reveal lower electron transport chain activity in ccRCCs that contributes to decreased oxidative and enhanced reductive TCA cycle labelling. However, ccRCC metastases unexpectedly have enhanced TCA cycle labelling compared with that of primary ccRCCs, indicating a divergent metabolic program during metastasis in patients. In mice, stimulating respiration or NADH recycling in kidney cancer cells is sufficient to promote metastasis, whereas inhibiting electron transport chain complex I decreases metastasis. These findings in humans and mice indicate that metabolic properties and liabilities evolve during kidney cancer progression, and that mitochondrial function is limiting for metastasis but not growth at the original site.

26 September 2022 in eLife
Verified
Journal Article
Open access
NLNicholas P Lesner
Nicholas P Lesner
XWXun Wang
Xun Wang
ZCZhenkang Chen
Zhenkang Chen
AFAnderson Frank
Anderson Frank
CMCameron J Menezes
Cameron J Menezes
PMPrashant Mishra
Prashant Mishra
Mitochondrial electron transport chain (ETC) dysfunction due to mutations in the nuclear or mitochondrial genome is a common cause of metabolic disease in humans and displays striking tissue specificity depending on the affected gene. The mechanisms underlying tissue-specific phenotypes are not understood. Complex I (cI) is classically considered the entry point for electrons into the ETC, and in vitro experiments indicate that cI is required for basal respiration and maintenance of the NAD+/NADH ratio, an indicator of cellular redox status. This finding has largely not been tested in vivo. Here, we report that mitochondrial complex I is dispensable for homeostasis of the adult mouse liver; animals with hepatocyte-specific loss of cI function display no overt phenotypes or signs of liver damage, and maintain liver function, redox and oxygen status. Further analysis of cI-deficient livers did not reveal significant proteomic or metabolic changes, indicating little to no compensation is required in the setting of complex I loss. In contrast, complex IV (cIV) dysfunction in adult hepatocytes results in decreased liver function, impaired oxygen handling, steatosis, and liver damage, accompanied by significant metabolomic and proteomic perturbations. Our results support a model whereby complex I loss is tolerated in the mouse liver because hepatocytes use alternative electron donors to fuel the mitochondrial ETC.

7 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
NLNicholas P. Lesner
Nicholas P. Lesner
BBBrooks Bailey
Brooks Bailey
DVDanny Vu
Danny Vu
ZWZheng Wu
Zheng Wu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Summary: Most kidney cancers display evidence of metabolic dysfunction 1–4 but how this relates to cancer progression in humans is unknown. We used a multidisciplinary approach to infuse 13 C-labeled nutrients during surgical tumour resection in over 70 patients with kidney cancer. Labeling from [U- 13 C]glucose varies across cancer subtypes, indicating that the kidney environment alone cannot account for all metabolic reprogramming in these tumours. Compared to the adjacent kidney, clear cell renal cell carcinomas (ccRCC) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in organotypic slices cultured ex vivo, indicating that suppressed labeling is tissue intrinsic. Infusions of [1,2- 13 C]acetate and [U- 13 C]glutamine in patients, coupled with respiratory flux of mitochondria isolated from kidney and tumour tissue, reveal primary defects in mitochondrial function in human ccRCC. However, ccRCC metastases unexpectedly have enhanced labeling of TCA cycle intermediates compared to primary ccRCCs, indicating a divergent metabolic program during ccRCC metastasis in patients. In mice, stimulating respiration in ccRCC cells is sufficient to promote metastatic colonization. Altogether, these findings indicate that metabolic properties evolve during human kidney cancer progression, and suggest that mitochondrial respiration may be limiting for ccRCC metastasis but not for ccRCC growth at the site of origin.

13 November 2026 in Cancer Research
Verified
Journal Article
Closed access
NCNathan J. Coffey
Nathan J. Coffey
SDSara M. Demczyszyn
Sara M. Demczyszyn
YXYizheng Xue
Yizheng Xue
ZZZian Zhang
Zian Zhang
NSNicolas Skuli
Nicolas Skuli
MSM. Celeste Simon
M. Celeste Simon
Metabolic reprogramming is a well-described hallmark of clear-cell renal cell carcinoma (ccRCC). Gene copy-number variation and altered gene expression data suggest that enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate (GLU)-derived glutathione (GSH) and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase (GLS) inhibitor CB-839 by providing GSH independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839–mediated GLS inhibition by decreasing GSH biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical GLU and GSH levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials, and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to GLS inhibition. Significance: Branched-chain amino acid transamination maintains essential glutamate and glutathione levels in glutamine-deprived clear cell renal cell carcinoma and can be targeted to sensitize tumors to glutaminase inhibition by impairing redox homeostasis.

21 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GLGraham P. Lobel
Graham P. Lobel
NHNanumi Han
Nanumi Han
WAWilliam A. Molina Arocho
William A. Molina Arocho
MSMichal Silber
Michal Silber
JSJason Shoush
Jason Shoush
MHMalay Haldar
Malay Haldar
Proliferating tumor cells take up glutamine for anabolic processes engendering glutamine deficiency in the tumor microenvironment. How this might impact immune cells is not well understood. Using multiple mouse models of soft tissue sarcomas, glutamine antagonists, as well as genetic and pharmacological inhibition of glutamine utilization, we found that the number and frequency of conventional dendritic cells (cDC) is dependent on microenvironmental glutamine levels. cDCs comprise two distinct subsets – cDC1 and cDC2, with the former subset playing a critical role in antigen cross-presentation and tumor immunity. While both subsets show dependence on Glutamine, cDC1s are particularly sensitive. Notably, glutamine antagonism did not reduce the frequency of DC precursors but decreased proliferation and survival of cDC1s. Further studies suggest a role of the nutrient sensing mTOR signaling pathway in this process. Taken together, these findings uncover glutamine dependence of cDC1s that is coopted by tumors to escape immune responses. One Sentence Summary Type 1 conventional dendritic cells require glutamine to maintain their number in non-lymphoid tissue. Significance Immune evasion is a key hallmark of cancer; however, the underlying pathways are diverse, tumor-specific and not fully elucidated. Many tumor cells avidly import glutamine to support their anabolic needs, creating a glutamine-deficient tumor microenvironment (TME). Herein, using mouse models of soft tissue sarcomas, we show that glutamine depletion in TME leads to reduced type 1 conventional dendritic cells – a cell type that is critical for adaptive immune responses. This work is a paradigm for how tumor cell metabolism can regulate anti-tumor immune responses and will be foundational to future efforts targeting glutamine metabolism for cancer immunotherapy.